Zhengye Biotechnology Holding ZYBT
NASDAQ ZYBT
$1.52 -0.02 (-1.30%)
As of: Nov 11, 2026 · 3:58 PM EST

Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2025)

Updated

Zhengye Biotechnology Holding (ZYBT) posted Current Deferred Revenue of $669,997 for the quarter ended Dec 31, 2025, up 38.1% from $485,167 a year earlier.

Analysis

Zhengye Biotechnology Holding (ZYBT) Current Deferred Revenue (2023 - 2025) Analysis & Trends

As of Dec 31, 2025, Zhengye Biotechnology Holding's Current Deferred Revenue came in at $680,000, up 42.6% from the prior year.

  • In prior years, Zhengye Biotechnology Holding's Current Deferred Revenue was $477,000 in the year ended Dec 31, 2024 (-13.2%) and $549,737 in the year ended Dec 31, 2023.
  • Quarterly Current Deferred Revenue has run from a low of $485,167 in the quarter ended Dec 31, 2024 to a high of $698,000 in the quarter ended Jun 30, 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Zhengye Biotechnology Holding 72.98 Mn 69.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 679,235.58
Jun 30, 2025 698,000.00
Dec 31, 2024 477,521.53
Dec 31, 2023 546,644.15
API Access

Zhengye Biotechnology Holding Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=ZYBT&period=max&api_key=YOUR_API_KEY